

Multicentre comparative clinical trial of the safety and efficacy of a 0.5% timolol-2% dorzolamide-0.2% brimonidine ophthalmic solution in fixed combination (formulated by Laboratorios Sophia S.A. de C.V.) versus Cosopt® in open angle glaucoma or ocular hypertension

Submission date 04/11/2008	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 23/12/2008	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 23/12/2008	Condition category Eye Diseases	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Leopoldo Baiza-Duran

Contact details
Hidalgo No. 861-A
Colonia Centro
Sector Hidalgo
Guadalajara
Mexico
44100
+52 (01)33 38264152
drbvista@sophia.com.mx

Additional identifiers

Protocol serial number

DRTBRI11O6

Study information

Scientific Title

Comparative trial of a 0.5% timolol-2% dorzolamide-0.2% brimonidine solution in fixed combination versus Cosopt® in open angle glaucoma or ocular hypertension

Acronym

KOEG

Study objectives

The hypotensive effect of 0.5% timolol-2% dorzolamide-0.2% brimonidine fixed combination is different from that of Cosopt® in patients with diagnosis of primary open-angle glaucoma (POAG) and/or ocular hypertension with or without pseudoexfoliation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Institute of Ophthalmology, Hospital La Carlota (Intituto de Oftalmologia Hospital La Carlota), gave approval on the 27th November 2006

Primary study design

Interventional

Study design

Phase II double-blind randomised controlled multicentre trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Primary open-angle glaucoma, ocular hypertension

Interventions

According to a random chart, 50 patients will receive over each eye one drop of a topical ophthalmic solution composed of timolol 0.5%, dorzolamide 2% and brimonidine 0.2% in a fixed-combination formula developed by Laboratorios Sophia S.A. de C.V. every 12 hours. The other 50 patients will be administered one drop of Cosopt® over each eye every 12 hours. Both medications will be administered during a period of 90 days. All the study articles will be labeled with a non-consecutive code number that is randomly generated by a computer.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Timolol, dorzolamide, brimonidine, Cosopt®

Primary outcome(s)

Intraocular pressure. Duration of follow-up: 3 months (90 days).

Key secondary outcome(s)

1. Visual fields. Duration of follow-up: 3 months (90 days).
2. Ocular surface fluorescein staining. Duration of follow-up: 3 months (90 days).

Completion date

31/05/2007

Eligibility

Key inclusion criteria

1. Patients must have a clinical diagnosis of mild to moderate primary open-angle glaucoma (POAG) with or without pseudoexfoliation and pigmentary dispersion or ocular hypertension
2. Both males and females, aged 18 years or older
3. Patients with intraocular pressure between 21 and 30 mmHg

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Patients with one blind eye
2. Patients with visual acuity of 20/40 or worse in either of the two eyes without a justifying cause
3. Patients with a history of any concomitant, active-stage ocular disease except the diseases specified in the inclusion criteria
4. Patients taking any medication, regardless of the route of administration, that decisively interferes with the study results, until 48 hours prior to start of the trial or until a time period in which residual effects could be present
5. Sulfa allergy
6. Patients with history of hypersensitivity or any medical situation that contraindicates or makes risky the use of any of the study articles or their compounds under any route of administration as well as any drug or formulation derived from them or related to them
7. Contact lens users

8. Women of childbearing potential who are not using an adequate contraceptive method, as well as pregnant or breast-feeding women
9. Patients with history of cataract surgery with or without intraocular lens (IOL) implant (pseudoaphakia or aphakia) three months or less prior to Day 1 of the trial
10. Patients enrolled in any medical trial out of the Laboratorios Sophia S.A. de C.V. sponsorship within the last 90 days prior to this trial
11. Legally disqualified or mentally disabled patients who cannot sign the informed consent to participate in this trial
12. Patients who cannot comply with the medical appointments or with all the protocol requirements
13. Patients who disagree to participate in this trial
14. Patients with optic disc excavation greater than or equal to 0.8
15. Normal-tension glaucoma patients

Date of first enrolment

01/01/2007

Date of final enrolment

31/05/2007

Locations

Countries of recruitment

Mexico

Study participating centre

Hidalgo No. 861-A

Guadalajara

Mexico

44100

Sponsor information

Organisation

Laboratorios Sophia S.A de C.V. (Mexico)

ROR

<https://ror.org/00zpf2822>

Funder(s)

Funder type

Industry

Funder Name

Laboratorios Sophia S.A. de C.V. (Mexico)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration